Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Antipsychotics and Metabolic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00636753
Recruitment Status : Suspended (this study has not finding place)
First Posted : March 14, 2008
Last Update Posted : July 30, 2010
Information provided by:
Glostrup University Hospital, Copenhagen

Brief Summary:
The purpose of the study is to determine whether antipsychotic treatment is influence psychiatric patients due to endocrine and metabolic status and quality of life.

Condition or disease
Metabolic Syndrome

Layout table for study information
Study Type : Observational
Estimated Enrollment : 60 participants
Observational Model: Cohort
Time Perspective: Prospective
Study Start Date : September 2008
Estimated Primary Completion Date : July 2009

Resource links provided by the National Library of Medicine

schizophrenic patients

Biospecimen Retention:   None Retained
whole blood, serum/plasma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients with debut of schizophrenia, controls from database

Inclusion Criteria:

  • Gender male
  • Age 18-45
  • Debut drug-naive schizophrenics,
  • Caucasians
  • Consent given to take part in the project

Exclusion Criteria:

  • Compliance-problems
  • Major lung-/kidney/hart/lever disorders
  • Abuse of alcohol/drugs
  • Diabetes 1 and 2
  • Antihypertensive
  • Anticholesterol-reducing medication
  • Patients under duress

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00636753

Layout table for location information
Psychiatric Center Glostrup
Copenhagen, Nordre Ringvej 28-69, Glostrup, Denmark, 2600
Psychiatric Center Glostrup
Nordre Ringvej 28-69, Glostrup, Denmark, 2600
Sponsors and Collaborators
Glostrup University Hospital, Copenhagen

Layout table for additonal information
Responsible Party:, centerchef Henrik Lublin, Psychiatric Center Glostrup Identifier: NCT00636753    
Other Study ID Numbers: HC-2007-0070
First Posted: March 14, 2008    Key Record Dates
Last Update Posted: July 30, 2010
Last Verified: July 2010
Keywords provided by Glostrup University Hospital, Copenhagen:
Metabolic and endocrine changes in schizophrenic patients by antipsychotics treatment.
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs